Across 83 European CTIS glioblastoma/glioma Phase I–III trial records, CROs or CRO-like operational providers are listed in 16 trials (19.3%). IQVIA is the most frequent named provider, appearing in 7 of 16 CRO-supported trials (43.8%), followed by PPD / Thermo Fisher and Medidata at 6 trials each (37.5%). CRO need is strongest when CTIS/EU submission and country coordination become complex: 9 of 11 trials spanning 5 or more countries (81.8%) used CRO support.
Provider activity is concentrated among a small set of global CRO and eClinical/lab vendors. IQVIA appears in 7 of 16 CRO-supported trials (43.8%), while PPD / Thermo Fisher and Medidata each appear in 6 of 16 trials (37.5%). Almac appears in 5 of 16 trials (31.3%), mainly around drug supply and clinical technology support.
The active CRO landscape is split between full-service operators and specialized providers. IQVIA, PPD / Thermo Fisher, ICON and Parexel signal broad operational outsourcing; Medidata, Almac, Labcorp and Q2 Solutions show that eClinical, supply-chain, and laboratory functions are central to glioma trial execution.
Country count is the strongest operational trigger. CROs are listed in only 1 of 51 single-country trials (2.0%), but in 6 of 21 trials spanning 2–4 countries (28.6%) and 9 of 11 trials spanning 5 or more countries (81.8%). CRO-supported trials averaged 5.4 countries and 19.3 sites, versus 1.5 countries and 5.6 sites for non-CRO trials.
For glioblastoma/glioma trials, CRO need is more closely tied to CTIS country coordination and site footprint than to participant volume alone. The practical trigger is not only enrollment size; it is the operational burden of running EU Part II submissions, local documents, contracts, monitoring and vendor oversight across multiple Member States.
CRO support is absent from pure Phase I trials (0 of 12) and rises in later or mixed-phase development. Phase II/III trials show 2 of 3 CRO use (66.7%), pure Phase III shows 6 of 21 (28.6%), and Phase I/II shows 5 of 21 (23.8%). Industry sponsorship is the clearest sponsor-level signal: 14 of 31 industry-sponsored trials (45.2%) used CROs versus 2 of 52 academic, hospital or non-profit trials (3.8%).
The highest-value CRO opportunity is not early single-site academic neuro-oncology; it is industry-led, later-stage or mixed-phase trials, especially those with orphan, paediatric, or multi-country execution complexity requiring structured CTIS and country-level operational support.
By dominant disease wording, CRO use is highest in IDH-mutant glioma records (3 of 4, 75.0%), low-grade / RAF-altered glioma records (3 of 5, 60.0%), and broader solid-tumor basket trials that include glioma (2 of 4, 50.0%). Classical glioblastoma/GBM records account for the largest absolute group but a lower CRO rate: 6 of 51 trials (11.8%).
The strongest CRO signal appears where biology, eligibility, biomarker handling, paediatric networks, or multi-arm basket execution add operational load. Classical glioblastoma is the largest volume segment, but many records are academic or narrower-country studies, which lowers the observed CRO rate.
The most common outsourced functions are full-service trial operations (12 of 16 CRO-supported trials, 75.0%), central laboratory / bioanalysis / PK-PD work (11 of 16, 68.8%), drug supply and logistics (10 of 16, 62.5%), imaging or central review (9 of 16, 56.3%), and data/eClinical systems (8 of 16, 50.0%).
Glioma outsourcing is not only monitoring. The recurring outsourced needs are CTIS-ready operations, biomarker and PK/PD lab infrastructure, imaging review, investigational product logistics, and data systems—functions that become harder to run internally when a study spans multiple EU countries.
CRO-supported trials account for 308 planned European sites and 1,564 planned participants. Spain, Germany, France and Italy carry 226 of those 308 CRO-supported sites (73.4%) and 1,227 of 1,564 CRO-supported planned participants (78.5%). CRO-supported trials also generated 84 country-level CTIS Part II submission/decision records, and 15 of 16 CRO-supported trials (93.8%) involved 2 or more countries.
The CRO opportunity is geographically concentrated in the major CTIS neuro-oncology operating markets. Spain, Germany, France and Italy should be treated as priority countries for EU submission planning, site activation, contracts, translations, and country-specific Part II package management.
Several adjacent questions are answerable from the same CTIS variables: whether CRO use follows scale, whether industry sponsors outsource more, which countries carry site burden, and which outsourced functions recur. The strongest numeric answers are summarized below.
A practical CRO targeting model should prioritize industry-led, orphan or paediatric glioma programs with 5+ CTIS countries, 6+ sites, and outsourced lab/imaging/data needs. These signals identify where EU submission and operational capacity are most likely to exceed internal sponsor resources.
CRO means contract research organization or named operational provider listed under CRO responsibilities in the sponsor data. CTIS means Clinical Trials Information System. CTIS Part II refers to the country-specific EU submission and assessment component, including national/site documents and local requirements. PK/PD means pharmacokinetic/pharmacodynamic analysis. EDC means electronic data capture.